Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory J Dore

Showing results (31-40 of 466) with videos related to

Pageof 47
Sort By:
Hepatology (Baltimore, Md.)|September 30, 2008
Tell me it ain't so: patient-to-patient transmission of hepatitis C in an endoscopy clinicGregory J Dore, Paul S Haber
Seminars in Liver Disease|February 26, 2005
Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfectionGregory J Dore, David L Thomas
Journal of Gastroenterology and Hepatology|August 19, 2008
HIV and hepatitis C coinfectionGail V Matthews, Gregory J Dore
Hepatology (Baltimore, Md.)|March 5, 2011
Optimal duration of treatment for acute hepatitis C in human immunodeficiency virus-positive individuals?Gail V Matthews, Gregory J Dore
JAMA|October 16, 2003
Cost-effectiveness of treatment for chronic hepatitis C infectionGregory J Dore, Hla-Hla Thein
Drug and Alcohol Review|June 15, 2007
Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reductionRichard Hallinan, Andrew Byrne, Gregory J Dore
Australian Prescriber|March 7, 2018
Observations on the launch of new drugs for hepatitis CMarianne Martinello, Behzad Hajarizadeh, Gregory J Dore
The Medical Journal of Australia|April 20, 2020
Hepatitis C elimination in Australia: progress and challengesMarianne Martinello, Behzad Hajarizadeh, Gregory J Dore
Gastroenterology Clinics of North America|May 12, 2020
Progress Toward Hepatitis C Virus Elimination: Therapy and ImplementationMarianne Martinello, Sahar Bajis, Gregory J Dore
Nature Reviews. Gastroenterology & Hepatology|August 24, 2017
Direct-acting antiviral agents for HCV infection affecting people who inject drugsJason Grebely, Behzad Hajarizadeh, Gregory J Dore
Pageof 47

Showing results (31-40 of 466) with videos related to

Sort By:
Pageof 47
Hepatology (Baltimore, Md.)|September 30, 2008
Tell me it ain't so: patient-to-patient transmission of hepatitis C in an endoscopy clinicGregory J Dore, Paul S Haber
Seminars in Liver Disease|February 26, 2005
Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfectionGregory J Dore, David L Thomas
Journal of Gastroenterology and Hepatology|August 19, 2008
HIV and hepatitis C coinfectionGail V Matthews, Gregory J Dore
Hepatology (Baltimore, Md.)|March 5, 2011
Optimal duration of treatment for acute hepatitis C in human immunodeficiency virus-positive individuals?Gail V Matthews, Gregory J Dore
JAMA|October 16, 2003
Cost-effectiveness of treatment for chronic hepatitis C infectionGregory J Dore, Hla-Hla Thein
Drug and Alcohol Review|June 15, 2007
Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reductionRichard Hallinan, Andrew Byrne, Gregory J Dore
Australian Prescriber|March 7, 2018
Observations on the launch of new drugs for hepatitis CMarianne Martinello, Behzad Hajarizadeh, Gregory J Dore
The Medical Journal of Australia|April 20, 2020
Hepatitis C elimination in Australia: progress and challengesMarianne Martinello, Behzad Hajarizadeh, Gregory J Dore
Gastroenterology Clinics of North America|May 12, 2020
Progress Toward Hepatitis C Virus Elimination: Therapy and ImplementationMarianne Martinello, Sahar Bajis, Gregory J Dore
Nature Reviews. Gastroenterology & Hepatology|August 24, 2017
Direct-acting antiviral agents for HCV infection affecting people who inject drugsJason Grebely, Behzad Hajarizadeh, Gregory J Dore
Pageof 47